For Immediate ReleaseOctober 27, 2021

Sumitomo Chemical Reports
Consolidated Financial Results
For the Half-Year Ended September 30, 2021
For the half-year ended on September 30, 2021, the Sumitomo Chemical Group
reported consolidated sales revenue of ¥1,325.2 billion, an increase of ¥278.4 billion
year on year, core operating income* of ¥148.9 billion, operating income of ¥144.3billion, and net income attributable to owners of the parent of ¥88.9 billion, all higher
than the results from the same period of the previous year.
Sumitomo Chemical decided to pay an interim dividend of ¥10 per share.
*Core operating income is a gain and loss concept, reflecting recurring earning
capacity, and deducts gains and losses incurred by non-recurring factors fromoperating income. It includes the share of profit from investments accounted for using
the equity method.
The financial results by business segment for the half-year are as follows:
Petrochemicals & Plastics
Market prices of petrochemical products, synthetic resins and synthetic fibers
increased due to recovery of demand and an increase in raw material prices. Margins
also improved. Therefore, sales revenue increased by ¥155.9 billion, to ¥399.5 billion,
and core operating income recovered by ¥73.3 billion, to ¥42.0 billion, compared withthe same period of the previous year, when the shipment volumes decreased due tothe periodic shutdown maintenance for Rabigh Refining and Petrochemical Company,
our equity method investee, and due to the impact of the COVID-19 pandemic, mainly
on demand for automotive use.

Energy & Functional Materials
Shipments of separators for lithium-ion secondary batteries performed well. Marketprices for aluminum and for the metal raw materials for cathode materials increased,resulting in higher selling prices. For the same period of the previous year, shipments
were lower, mainly for automotive use, due to the COVID-19 pandemic. As a result,sales revenue increased by ¥43.2 billion from the same period of the previous year, to¥148.5 billion. Core operating income increased by ¥7.8 billion from the same periodof the previous year, to ¥12.6 billion.
IT-related Chemicals
Shipments of processing materials for semiconductors (including high purity
chemicals and photoresists) increased, driven by growing demand for these items.
Shipments of materials for display applications increased in the face of stay-at-homedemand, and telework demand continued from the previous year. As a result, sales
revenue increased by ¥14.4 billion from the same period of the previous year, to ¥227.7
billion, and core operating income increased by ¥7.4 billion from the same period of
the previous year, to ¥29.5 billion.
Health & Crop Sciences
Shipments of crop protection products in North America, South America and India
stayed firm. Market prices of methionine (feed additives) increased from the sameperiod of the previous year. As a result, sales revenue increased by ¥23.4 billion fromthe same period of the previous year, to ¥209.4 billion. Core operating income
increased by ¥9.1 billion from the same period of the previous year, to ¥18.5 billion.



Pharmaceuticals
In North America, Orgovyx™ (therapeutic agent for advanced prostate cancer), which
was launched in the previous fiscal year, and Gemtesa® (therapeutic agent for
overactive bladder) and Myfembree® (therapeutic agent for uterine fibroids), both ofwhich commenced sales in the last quarter, as well as the recording of a lump-sum
upfront payment for a development and commercial collaboration and license
agreement, contributed to sales revenue. These more than offset negative impacts,
such as declines in sales of Latuda® (atypical antipsychotic agent) and Brovana®
(therapeutic agent for chronic obstructive pulmonary disease), the latter of which saw
its exclusive marketing period expire. On the other hand, in Japan, sales revenues
were adversely affected by the National Health Insurance (NHI) drug price revisions.
As a result, sales revenue increased by ¥33.4 billion from the same period of theprevious year, to ¥309.6 billion. Core operating income increased by ¥0.9 billion fromthe previous year, to ¥50.0 billion, because of the increase of sales revenue, thoughselling, general and administrative expenses increased due to the start of full-scale
marketing activities by subsidiaries of Sumitovant Biopharma Limited.
OthersIn addition to the above five segments, the Sumitomo Chemical Group supplies
electric power and steam, designs chemical plants and supervises the constructionof those facilities, provides transportation and warehousing, and conducts physicalproperty analysis and environmental analysis. Sales revenue of these businesses
increased by ¥8.1 billion from the same period of the previous year, to ¥30.6 billion,
and core operating income increased by ¥1.1 billion from the same period of theprevious year, to ¥6.8 billion.

Summary of Consolidated Results(1) Results of Operations:
Sales revenue
Core operating income(Share of profit of investments
accounted for using the equity method)
Operating income
Income before taxes
Net income
Net income attributable tonon-controlling interests
Net income attributable toowners of the parent

Net income per 1,000 shares

Comprehensive income(6 Months ended
September 30, 2021
USD (Thousands)*1
Yen (Millions)
1,325,210
11,840,690
148,897
1,330,388
27,239 )(243,379 )6 Months ended
September 30, 2020 *2
Yen (Millions)
1,046,771
53,477((22,973) )144,272
146,781
107,810

1,289,064
1,311,481
963,277

50,18838,252
14,27018,926

169,103

16,51488,884

794,174(2,244)

Yen
54,364

USD*1486

Yen(1,372)

Yen (Millions)
82,317

USD (Thousands)*1
735,499

Yen (Millions)(10,502)

As of September 30, 2021
USD (Thousands)*1
Yen (Millions)
4,082,799
36,479,619
1,547,759
13,829,155

As of March 31, 2021
Yen (Millions)
3,990,254
1,482,119

6 Months ended
September 30, 2021
USD (Thousands)*1
Yen (Millions)
77,198689,761(65,150)(582,112)(27,148)(242,566)
346,805
3,098,687

6 Months ended
September 30, 2020 *2
Yen (Millions)
156,585(62,963)
97,937
381,802

6 Months ended
September 30, 2021
USD (Thousands)*1
Yen (Millions)

6 Months ended
September 30, 2020 *2
Yen (Millions)䚷(2) Financial Position:
Total assets
Total equity(3) Cash Flows:
Cash flows from operating activities
Cash flows from investing activities
Cash flows from financing activities
Cash and cash equivalents at end of period(4) Results of Operations by
䚷䚷䚷Business Segment:
Sales revenue
Petrochemicals & Plastics
Energy & Functional Materials
IT-related Chemicals
Health & Crop Sciences
Pharmaceuticals
OthersCore operating income
Petrochemicals & Plastics
Energy & Functional Materials
IT-related Chemicals
Health & Crop Sciences
Pharmaceuticals
OthersAdjustments

399,485
148,477
227,656
209,427
309,580
30,585
1,325,210

3,569,380
1,326,635
2,034,096
1,871,221
2,766,083
273,275
11,840,690

243,630
105,229
213,259
186,050
276,141
22,462
1,046,771

42,043
12,57329,524
18,45649,963
6,781(10,443)
148,897375,652
112,339
263,796
164,904
446,41760,588(93,308)
1,330,388(31,283)
4,769
22,1399,325
49,054
5,668(6,195)53,477(Note)
䚷 *1䚷U.S. dollar amounts are translated from yen, for convenience only, at the rate of䚷 ¥111.92 = $1 prevailing on September 30, 2021.
䚷*2䚷Previous half-year results were adjusted retrospectively because the temporary accounting treatment related
to business combinations was finalized.